Amarin Corp Plc (AMRN)

[sts66]

Best in class drug but a vanishingly small market - about 1.5M in the US have lupus, 2%-3% go on to develop severe kidney disease that AUPH's drug treats, active lupus nephritis - that's only 45k people - not surprised sales aren't good - might stay that way too. Did they get orphan drug status, is the drug expensive enough for them to make money while GIA? I doubt their reps would face the same resistance AMRN reps face (it's just fish oil), but still could be a hard sell with such a small target population. If I wanted to place a spec bet on a biotech it would be IBRX or NRXP - have already gotten as much IBRX as I want.